Vor Biopharma (VOR) EBITDA (2020 - 2026)

Vor Biopharma (VOR) has 7 years of EBITDA data on file, last reported at -$220.3 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$220.3 million, down 578.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$883.8 million (down 645.92% YoY), and the FY2025 annual result was -$696.0 million, down 495.78% from the prior year.
• EBITDA declined to -$220.3 million in Q1 2026 per VOR's latest filing, from $1.7 billion in the prior quarter.
• Over five years, EBITDA peaked at $1.7 billion in Q4 2025 and troughed at -$1.6 billion in Q2 2025.
• A 5-year average of -$73.1 million and a median of -$27.8 million in 2023 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 5701.43% in 2025 and fell as far as 5556.24% in 2025.
• A 5-year view of EBITDA shows it stood at -$23.5 million in 2022, then declined by 10.88% to -$26.1 million in 2023, then declined by 18.04% to -$30.8 million in 2024, then soared by 5701.43% to $1.7 billion in 2025, then slumped by 112.79% to -$220.3 million in 2026.
• Business Quant data shows VOR's EBITDA at -$220.3 million in Q1 2026, $1.7 billion in Q4 2025, and -$812.7 million in Q3 2025.